Medication info

Anguk Lina Duo Tablet 2.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Anguk Pharm Co., Ltd.
Appearance
Bright pink, convex oval film-coated tablet
Packaging
30 tablets (10 tablets/PTP packaging x 3)
Approval status
Active

MFDS item code 201801848 · Approved 2018.04.30

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose for each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should start at their current doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. 5. Patients with inadequate glycemic control on concomitant insulin and metformin therapy: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching patients treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Anguk Pharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This drug is used in conjunction with dietary management and exercise to help control blood sugar levels in adults with type 2 diabetes. It is administered in cases where previous diabetes treatments were not used, and blood sugar control is difficult with monotherapy; it is also used when metformin alone is insufficient. Additionally, when transitioning from the combination of linagliptin and metformin or when blood sugar control is inadequate with the combination of metformin and sulfonylurea, this drug is co-administered with sulfonylurea. If control is also difficult with the combination of insulin and metformin, this drug is used in conjunction with insulin, and it is also used when there is insufficient effect in combination with metformin and empagliflozin. This drug is effective in improving blood sugar control at various stages of therapy.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose for each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this medicine twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from concomitant linagliptin and metformin therapy: Patients switching from concomitant linagliptin and metformin therapy to this medicine should start at their current doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. 5. Patients with inadequate glycemic control on concomitant insulin and metformin therapy: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching patients treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This drug helps manage blood sugar levels. However, during treatment, there may be a rare side effect called lactic acidosis, which can occur when lactic acid builds up excessively in the body, leading to a dangerous condition, so caution is needed. Patients with allergies to any components of this drug, as well as those with type 1 diabetes, severe renal impairment, acute heart disease, liver dysfunction, acute alcohol intoxication, or those who are pregnant or breastfeeding should not take this drug. When taken with other diabetes medications or insulin that pose a risk of hypoglycemia, attention to hypoglycemic symptoms is necessary, and dose adjustments may be required if needed. Patients with decreased renal function should undergo kidney function tests before taking this drug and regularly monitor kidney function. In situations that could affect kidney function, such as acute infections, dehydration, severe trauma, or pre- and post-surgery, this drug should be temporarily discontinued. Rare side effects such as acute pancreatitis or bullous pemphigoid with blisters on the skin can occur, so if abdominal pain or skin abnormalities appear during treatment, immediate consultation with healthcare professionals is necessary. This drug may lower vitamin B12 levels, so regular monitoring of vitamin B12 levels is advisable for long-term use. When used in combination with other drugs, there may be potential interactions, so it is essential to inform healthcare professionals about any other medications being taken, especially those that could affect kidney function. Women who are pregnant or planning to become pregnant, as well as those who are breastfeeding, should not use this drug, and its safety and effectiveness have not been established in children and adolescents. Elderly patients may have decreased renal function, so it is important to frequently check renal function and start treatment at the lowest dose. In case of overdose, gastrointestinal disturbances or lactic acidosis may occur, requiring immediate medical treatment, and it should be stored out of the reach of children and kept away from moisture.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • reduced and deficient vitamin B12
  • hypoglycemia
  • taste disturbances
  • cough
  • appetite loss
Show 125 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe joint pain with disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • septicemia
  • pneumonia
  • gastroenteritis
  • shingles
  • cystitis
  • cerebral infarction
  • speech disorders
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • renal transplantation failure
  • anxiety
  • mood disorders
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • diabetic neuropathy
  • headache
  • sensory abnormalities
  • postherpetic neuralgia
  • hemiparesis
  • syncope
  • drowsiness
  • chest discomfort
  • asthenia
  • pain
  • epistaxis
  • oropharyngeal pain
  • vocal disorders
  • nasal bleeding
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • osteoarthritis
  • limb pain
  • increased ALT
  • increased AST
  • itching
  • insomnia
  • hypertension
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndromes
  • vocal cord polyps
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • dizziness
  • increased blood creatinine
  • facial edema
  • hyperthermia
  • back pain
  • rotator cuff syndrome
  • confused state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly closed container to prevent air or moisture from entering, preferably at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Bright pink, convex oval film-coated tablet

Package unit

30 tablets (10 tablets/PTP packaging x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.